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Integrin b1 is both overexpressed and in an ‘active’ conformation in vulval squamous cell carcinomas (VSCCs) compared to matched
normal skin. To investigate the significance of integrin b1 deregulation we stably knocked-down integrin b1 expression in the VSCC
cell line A431. In vitro analysis revealed that integrin b1 is required for cell adhesion, cell spreading and invasion. However, integrin b1
is not required for cell growth or activation of FAK and ERK signalling in vitro or in vivo. Strikingly, while control tumours were able to
invade the dermis, integrin b1 knockdown tumours were significantly more encapsulated and less invasive.
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Interactions between keratinocytes and the extracellular matrix
(ECM) are crucial for epidermal tissue architecture, cell prolifera-
tion and cell survival (Hynes, 2002). The integrin family ECM
receptors are key mediators of these interactions and are
frequently deregulated in skin disorders (Watt, 2002) and
neoplasias (Parise et al, 2000). Integrin-mediated cell adhesion is
required for cell motility and also affects cell proliferation and
survival in many systems (Schwartz and Assoian, 2001). Integrins
function as membrane spanning heterodimers consisting of an a
subunit and a b subunit. To date, 18 a and eight b subunits have
been identified and these can associate in numerous different
combinations with different ligand specificities (Hynes, 2002).
Integrin b1 can bind to various ECM components depending on its
a subunit partner: the heterodimers a2b1, a3b1 and a5b1 bind
preferentially to collagen, laminin and fibronectin, respectively.
The intracellular tail of integrin b1 is linked to the actin
cytoskeleton via association with proteins such as talin, a-actinin
and vinculin (Brakebusch and Fassler, 2003). Integrin b1 is crucial
for cell motility in a number of contexts; it is required for efficient
keratinocyte wound healing in vivo (Grose et al, 2002) and for the
collective movement of tumour cells (Hegerfeldt et al, 2002).
Integrins also indirectly recruit a range of signalling molecules
including EGFR, FAK and Src-family kinases (Giancotti and
Ruoslahti, 1999; Yamada and Even-Ram, 2002). Activation of these
signalling molecules following integrin engagement can promote
the activation of the small GTPase Ras leading to increased and
sustained ERK/Map kinase signalling, which may in turn affect cell
proliferation (Renshaw et al, 1996; Roovers et al, 1999).
In normal skin integrin b1 expression is restricted to the basal
layer of stem and transit amplifying cells. Loss of integrin b1 in the
skin leads to blistering, failure in basement membrane organisa-
tion and hemidesmosome instability (Raghavan et al, 2000). In
contrast, forced expression of integrin b1 in the suprabasal layer of
the epidermis antagonises cell differentiation and cell cycle exit
(Carroll et al, 1995), possibly by promoting ERK/MAP kinase
activity (Zhu et al, 1999). Consistent with a role in promoting
proliferation, integrin b1 is mutated in an oral squamous cell
carcinoma cell line (Evans et al, 2003) and its expression is
increased in upper aerodigestive tract (Van Waes et al, 1995) and
cervical SCC (Hughes et al, 1994). Contrastingly, other studies
have reported reduced expression in oral SCC (Jones et al, 1993).
Vulval squamous cell carcinoma (VSCC) has an incidence of 2/
100000 per year in industrialised countries. Five-year survival
drops from 90% for those with FIGO Stage I disease at presentation
to 18% for women with Stage IV. Death from VSCC is caused by
tumour invasion into local tissues resulting either directly in
haemorhage, sepsis or uraemia from bilateral ureteric obstruction
or indirectly in inanition. There are two distinct patterns of VSCC
invasion into surrounding tissue: a ‘pushing’ pattern displays
distinct tumour–stroma boundaries, whereas a ‘spray’ pattern of
invasion is characterised by ill-defined tumour–stroma bound-
aries with small clusters of invading cells and correlates with poor
prognosis (Heaps et al, 1990; Qureshi et al, 1999). Understanding
the molecular mechanisms of VSCC invasion will aid developing
strategies to combat this life-threatening aspect of the disease. In
this study, we have analysed the expression of integrin b1 and
its major a subunit partners in matched VSCC and normal
skin samples. Integrin b1 is more highly expressed in VSCC; to
address the functional significance of this change we have
abrogated integrin b1 expression in the VSCC cell line A431. This
approach has allowed the role of integrin b1 in tumour to be
analysed in vivo. We find that integrin b1 is not required for
proliferation of VSCC cells in vivo but is important for invasive
tumour margins.
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Cell culture, transfection and tumour experiments
A431 cells were obtained from the ATCC and routinely maintained
in 10% FCS DMEM. Cells were transfected using Lipofectamine
2000 in accordance with the manufacturer’s instructions: briefly,
subconfluent cells were transferred into Optimem-1 for transfec-
tion and incubated with a mixture containing 0.7mg of DNA and
4ml of Lipofectamine 2000 for 5h. The plasmid to reduce integrin
b1 expression contained the sequence GGAACAGCAGAGAAGC
TCATTCAAGAGATGAGCTTCTCTGCTGTTCCTTTTT subcloned
immediately downstream of the human RNA polymerase III H1
promoter bases  245 to  1; this sequence was subcloned into the
EGFP-C1 (Clontech) backbone cut with AseI and HpaI to remove
the entire CMV-GFP expression cassette. An equivalent empty
vector was used as a control. Stably transfected clones were
selected with 600mgml
 1 of G418. One million cells were injected
subcutaneously into the flank of female MF1 nude mice. Tumour
size was recorded at regular intervals and the tumours were
analysed when they had reached an average diameter of 1cm.
Analysis of tumour samples
Following approval by the Committee for Clinical Research
and the Research Ethics Committee of the Royal Marsden
NHS Trust tumour samples were collected from 14 consenting
women.
Preparation of frozen sections Specimens were mounted onto
cork discs with tissue-tek OCT compound (Sakura; 4583), and
frozen in either liquid nitrogen or dry ice. 7 or 8mm sections were
cut and mounted onto electrostatic slides (Surgipath Superfrost
‘Plus’ white; 08143G). The slides were allowed to air dry and then
fixed in 4% formaldehyde/PBS for 10min followed by permeabi-
lisation in 0.2% Triton X-100/PBS for 5min. Samples were
incubated overnight at 4C with primary antibodies diluted 1:100
in PBS/3% BSA/0.1% Tween before washing in PBS and incubation
for 1h at 37C with secondary antibodies diluted 1:100 in PBS/3%
BSA/0.1% Tween. The antibodies used were as follows: anti-Pan
integrin b1 (P5D2 – Santa Cruz sc13590), antiactive b1-integrin:
(9EG7 – BD pharmingen 550531) and (HUTS-21 – BD pharmingen
556048), blocking b1-integrin (AIIB2) was a gift from F Watt, anti-
integrin a2 (Sigma I6403), anti-integrin a3 (Santa Cruz sc-13545),
anti-integrin a5 (Santa Cruz sc-13547), anti-integrin a6 (Santa
Cruz sc-13542), anti-integrin aV (Santa Cruz sc-9969), antikeratin
14 (Covance PRB-155P), antilaminin B2 (Upstate 05-206), antipho-
sphoY118 paxillin (Biosource 44-722), antivinculin (Sigma V-
9131). Images were captured using a Biorad MRC1024 confocal
microscope; to enable comparison of tumour and normal tissue
images were acquired using the same settings. Quantification of
the fluorescence was performed using Image J, the mean pixel
intensity was compared between the normal epidermis (basal and
differentiating cells were analysed together) and the tumour
sample from each patient. Haematoxylin and eosin staining was
carried out using standard procedures.
Preparation of lysates Specimens were snap frozen in liquid
nitrogen then crushed with a pestle and mortar surrounded by
liquid nitrogen to prevent defrosting. The powdered sample was
transferred into an eppendorf tube and 1ml of lysate buffer added
(20mM TrisCl, 40mM Na pyrophosphate, 50mM NaF, 5mM MgCl2,
100mM Na vanadate, 10mM EGTA, 1% Triton X-100, 0.5%
NaDeoxycholate and protease inhibitors). The sample was
repeatedly passed through a 21G needle and centrifuged at
16000g for 5min. The supernatant was analysed by Western
blotting. The antibodies used were as follows: phospho-ERK1/2
(Sigma M8159), ERK1/2 (Transduction labs 554093), phospho-
FAK (Affinity BioReagents OPA1-03071), FAK (Upstate Biotech
05-537).
Flow cytometry
Subconfluent cells from a 6-cm dish were detached using cell
dissociation buffer (Gibco/BRL 13150-016) before centrifugation at
250g. They were then resuspended in 200ml of PBSþ1mgml
 1
P5D2. After incubation on ice for 1h, cells were washed repeatedly
by centrifugation at 250g followed by resuspension in PBS. Cells
were then incubated for 30min on ice in 200ml of PBSþFITC anti-
mouse antibodies (Jackson Stratech) before washing with PBS and
analysis using a Becton Dickinson flow cytometer.
Immune-fluorescence
Cells were fixed using 4% formaldehyde diluted in PBS for 15min
before permeabilisation with 0.2% Triton X-100 diluted in PBS.
Samples were subsequently treated as described above for frozen
tissue sections.
Cell adhesion, spreading and invasion assays
Adhesion assays were performed using the cytomatrix screen kit
(Chemicon International) according to their protocol. Cells that
had been detached using Cell Dissociation Buffer (Gibco/BRL
13150-016) were allowed to attach to either collagen I, collagen IV,
or fibronectin for 10min before washing to remove nonadherent
cells followed by fixation of adherent cells. The adherent cells were
stained with crystal violet and quantified using a plate reader.
AIIB2 was incubated with cells at 0.05mgml
 1 for 10min prior to
the start of the adhesion assay. Cell spreading was determined by
re-plating cells that had been detached using Cell Dissociation
Buffer on either Collagen I or Fibronectin coated dishes in 1% FCS
(BD BioCoat Variety Pack 354431) and recording their behaviour
by time-lapse microscopy. Images were captured every 2min and
scored manually for the proportion of cells with a spread
morphology. For Western blot analysis, cells were handled as
described for the cell spreading assay; cells were lysed directly by
the addition of SDS–PAGE loading buffer to the dish. The lysate
was then transferred to an eppendorf tube and sonicated to disrupt
DNA.
Inverse cell invasion assays were performed as previously
described (Hennigan et al, 1994) using Transwell dishes with 8mm
pores (Costar 3422) and Matrigel (BD Bioscience 354234) diluted
1:1 with DMEM. Cells were fixed and stained with phalloidin and
propidium iodide. A confocal microscope was used to identify cells
that had migrated through the 8mm pores and at least 10mm into
the Matrigel: the percentage of invasive cells (calculated relative to
the total number of cells in the z stack) was determined for at least
three fields per experiment.
RESULTS
Increased integrin b1 expression in VSCC
VSCC and normal vulval skin tissue pairs were obtained from 14
women. Multichannel immunofluorescence on cryostat sections
was used to compare integrin b1 expression between VSCC and
normal vulval skin from the same patient. Three different
monoclonal antibodies were used to detect integrin b1: P5D2
recognises integrin b1 regardless of its conformation, whereas
9EG7 and HUTS21 only recognise integrin b1 that is either
competent to bind ligand or bound to ligand – this is often
considered to reflect integrin b1 in its active conformation (Lenter
et al, 1993; Bazzoni et al, 1995; Luque et al, 1996). Staining with
P5D2 revealed that in normal vulval epidermis integrin b1i s
expressed in the basal layer of cells in contact with the basement
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smembrane and a small number of cells in the suprabasal layer
(Figure 1A). Furthermore, staining with 9EG7 revealed that
integrin b1 is in its ligand-bound conformation in these cells
(Figure 1A). Integrin b1 staining with P5D2 and 9EG7 antibodies
increased in the tumours of 11 out of 12 and nine out of 12 cases,
respectively (Table 1). This reflected both an increased proportion
of cells staining and increased intensity of staining (Figure 1A).
Furthermore, the localization of integrin b1 was no longer
restricted to basal and lateral membranes. Staining with a second
conformation-specific antibody, HUTS21, and gave similar results
to 9EG7 confirming that there are increased levels of ligand-bound
or ‘active’ integrin b1 in VSCC compared to matched normal skin
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Figure 1 Altered integrin expression in vulval squamous cell carcinoma. (A) Panels show three channel fluorescence images of DNA (left), total integrin
b1-P5D2 (left-mid), and ‘active’ integrin b1-9EG7 (right-mid) staining in normal and tumour tissue from the same patient. Orange line indicates the boundary
between the epidermis and dermis in normal tissue. Normal and tumour tissue stained with no primary antibody (right). (B) Panels show fluorescence
images of ‘active’ integrin b1-HUTS21 staining (green) and laminin B2 (red) in normal and tumour tissue from the same patient. ‘lat’ indicates lateral
membrane staining. (C) Panels show three channel fluorescence images of F-actin (red in left panels), keratin 14 (blue in left panels), integrin b1-P5D2
(upper right panel) staining, and ‘active’ integrin b1-HUTS21 (lower right panel). Orange line indicates boundary between the tumour and stroma. (D)
Panels show fluorescence images of integrin a2 (left panels), integrin a3 (left-mid panels), integrin a5 (right-mid panels) and integrin aV (right panels) in
normal and tumour tissue (pairs of samples are from the same patient). Orange line indicates the boundary between the epidermis and dermis in normal
tissue.
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recognises integrin b1 at both basal and lateral membranes
(Figure 1B – also similar pattern in Figure 1A). These data suggest
that integrin b1 is binding to nonbasement membrane ligands
along the lateral membranes in vulval epithelia. Integrin b1
expression was also detected in the dermis. Control analysis
confirmed that the staining observed was dependent upon the
primary antibody and that secondary antibodies did not crossreact
(Figure 1A and data not shown).
All three integrin b1 antibodies stained the tumour sections
somewhat heterogeneously; detailed examination of the staining
pattern suggested that integrin b1 staining was greatest in regions
close to stromal cells. To confirm this we performed three-channel
immunofluorescence to simultaneously stain for integrin b1 and
markers that would help identify the tumour boundary. We used a
combination of keratin 14 staining, which is commonly expressed
in keratinocyte-derived neoplasias, and phalloidin, which strongly
stains cortical F-actin in tumour cells, to delineate the tumour
boundary. This was compared with either P5D2 or HUTS21
staining in the same section. The tumour/stroma interface is
highlighted in Figure 1C, both total and active integrin b1 staining
is increased in the cells at the tumour/stroma boundary.
Integrin b1 can associate with many different a subunits.
Previous studies have suggested that the main a subunits
expressed in epidermal tissue are a2, a3, a5, a6 and aV (Hertle
et al, 1991; Hodivala et al, 1994); we therefore examined if the
expression of these a subunits changed between the normal and
tumour tissue. In normal skin, integrin a2 and a3 were expressed
in the basal layer of cells and localised to the lateral membranes.
Integrin a2 and a3 staining was increased in nine out of 12 and 12
out of 12 tumour samples, respectively (Figure 1D and Table 1).
Integrin aV was expressed throughout the normal epidermis and
its expression increased modestly in the tumour tissue (Figure 1D
and Table 1); this differs from cervical epidermis where integrin
aV distribution is restricted to the basal layer of cells (Hughes et al,
1994) and may be unique to vulval epidermis. The expression of
integrin a4 was somewhat variable between samples. Integrin a5
and a6 staining was present in the basal layer of normal epidermis
and was increased in most tumour samples, although not as
dramatically as integrin b1 (Figure 1D and Table 1).
Generation of integrin b1 knockdown VSCC cell lines
To investigate the functional significance of integrin b1 over-
expression in VSCC we sought to knockdown integrin b1
expression in an appropriate cell line. A431 cells are derived from
a VSCC and are amenable to standard cell culture techniques. To
reduce integrin b1 levels we cloned an inverted repeat of an siRNA
sequence that is capable of reducing the expression of all integrin
b1 isoforms (Vial et al, 2003) downstream of the RNA polymerase
III H1 promoter (Brummelkamp et al, 2002; Hannon, 2002). This
construct or an empty vector control was transfected into A431
cells and G418-resistant clones were selected and screened for
integrin b1 expression by using immunofluorescence. Six of the 28
G418 clones screened had no detectable integrin b1 expression in
immunofluorescence assays. These clones were further screened by
flow cytometry for a more quantitative analysis of integrin b1
expression. Figure 2A shows the integrin b1 expression in three
clones that were chosen for further analysis compared to a control
pool of cells stably transfected with the empty vector. All three
clones had homogeneous profiles of integrin b1 expression; clones
4 and 20 had a roughly 18-fold reduction in expression and clone
19 a 50-fold reduction. Flow cytometry analyses the levels of
integrin b1 at the cell surface, to exclude the possibility that these
clones expressed intracellular integrin b1 we performed confocal
microscopy analysis. In control cells integrin b1 was localised at
the cell periphery, while in clones 4, 19 and 20 no staining was
detected either at the cell surface or in the cytoplasm (Figure 2B
and data not shown). These results demonstrate the generation of
three-independent A431 cell lines with dramatically reduced
integrin b1 expression.
Previous studies have shown that knocking out integrin b1
affects the expression of other integrin subunits (Brakebusch et al,
1999; Guan et al, 2001); we therefore tested if expression of other
integrin subunits was altered in the integrin b1 knockdown clones
we generated. Quantitative immune-fluorescence was used to
determine the relative levels of integrin expression in control and
integrin b1 knockdown cells. No significant difference in the
expression of integrins b3, b4, a2 and a6 was seen between control
and the knockdown cell lines (Table 2 and data not shown).
However, we noted dramatic reductions in the expression of
integrins a3 and a5 in all three integrin b1 knockdown clones and
a modest increase in integrin aV expression. Therefore, loss of
integrin b1 expression affects the levels of other integrin subunits
within the cell.
Integrin b1 is required for cell adhesion, spreading and
invasion
Since integrin b1 is a mediator of cell attachment to the
extracellular matrix at focal adhesions we investigated if cells
lacking integrin b1 retained focal adhesions. Figure 2C shows that
both control and integrin b1 knockdown cells had peripheral
vinculin and phospho-paxillin staining characteristic of focal
adhesions. Interestingly, these often extended perpendicular to the
cell border in control cells but were less extended in the integrin b1
knockdown cells.
Previous work has shown that integrin b1 is required for cell
adhesion and migration; to determine if reduced integrin b1
expression affects the behaviour of VSCC cells we investigated the
ability of these cells to adhere to different matrices. Cells were
allowed to adhere for 10min before washing and quantification of
the number of attached cells. Figure 3A shows that reduced
integrin b1 expression prevents efficient cell adhesion to collagen I
and collagen IV, but not fibronectin (at longer timepoints the
differences between the control and knockdown cell lines became
much less pronounced, data not shown). In contrast, interference
with integrin b1 function using the blocking antibody AIIB2
prevented adhesion to all three substrates (Werb et al, 1989).
While adhesion to fibroncetin did not appear to be compromised
by b1 knockdown, spreading was compromised (see below).
Following the initial event of cell adhesion, adherent cells flatten
and adopt a ‘spread’ morphology. It is believed that integrin-
Table 1 Changes in integrin expression in VSCC
Change in staining (tumour vs normal tissue)
Integrin o0.66 0.66–1.5 1.5–5 5–20 420
b1 (P5D2) — 1 3 3 5
b1 (9EG7) — 3 1 3 5
b1 (HUTS21)
a —11 3 —
a21 2 5 3 1
a3— — 6 4 2
a4
b 223 1 2
a5— 2 7 — 3
aV1 2 6 3 —
a61 1 4 3 1
Paired normal vulval skin and VSCC samples were analysed for integrin expression by
immunohistochemical methods. The amount of fluorescence was quantified from
images taken using a confocal microscope. The table shows the fold change in integrin
staining in the tumour relative to the normal epidermis from the same patient.
Changes of 0.66–1.5 are regarded as no change.
aOnly five samples were stained
with HUTS21.
bTwo samples had no detectable integrin a4 staining.
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spreading process (Defilippi et al, 1999). We next investigated
whether integrin b1 is required for cell spreading. Cells in
suspension were added to plates coated with either collagen I or
fibronectin and their morphology was monitored using time-lapse
videomicroscopy. Control A431 cells changed from a rounded
morphology to a flat spread morphology within 12min of plating
on collagen I coated dishes (Figure 3B, left). In contrast, in all three
integrin b1 knockdown clones, the majority of cells were not
spread at this time and even after 100min only between 25 and
60% of the cells were spread. Both control and integrin b1
knockdown cells began to spread at a similar rate on fibronectin
coated plates (Figure 3B right); these data are consistent their
similar abilities to adhere to fibronectin (Figure 3A). How-
ever, integrin b1 knockdown cells failed to continue spreading
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Figure 2 Analysis of integrin b1 knockdown cell lines. (A) Flow cytometry analysis of integrin b1 expression. Control and integrin b1 knockdown clones
were stained using P5D2 anti-integrin b1 antibody or no antibody and 10000 cells analysed by flow cytometry. (B) Control and integrin b1 knockdown cells
(clone 20 shown) were stained with P5D2 antiintegrin b1 antibody (green) and phalloidin to visualise F-actin (red). (C) Control and integrin b1 knockdown
cells (clone 4 shown) were stained with phalloidin to visualise F-actin (left) and vinculin (middle) and phospho-Y118 paxillin (right) to visualise focal
adhesions.
Table 2 Changes in integrin expression in integrin b1 knockdown cell
lines
Integrin
Change in expression
(knockdown cells relative to control)
a2 0.80 (70.61)
a3 0.01 (70.0)
a5 0.12 (70.14)
aV 3.80 (71.97)
a6 1.12 (70.46)
The expression of integrin a-subunits relative to control cells was analysed in integrin
b1 knockdown cell lines by quantitative immune-fluorescence. The results for the
three knockdown cell lines (#4, #19 & #20) were averaged to produce the numbers
shown above – standard deviation is shown in parentheses.
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s12–16min after plating while the proportion of spread control
cells increased further (Figure 3B, right). Similar results were
obtained using the integrin b1 function blocking antibody AIIB2
(data not shown). These data demonstrate that integrin b1i s
required for the ability of A431 cells to adhere and spread on
collagen I and to spread efficiently on fibronectin.
We next tested if integrin b1 is required for cells to invade into a
three-dimensional matrix. For this study we used Matrigel, which
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Figure 3 Integrin b1 is required for cell adhesion, spreading and invasion. (A) Control A431 cells with or without integrin b1 blocking antibody AIIB2 and
integrin b1 knockdown cells were assayed for their ability to adhere to collagen I, IV or fibronectin using Chemicon cytomatrix screen kits. Results are
average of two experiments, error bars indicate the standard deviation. (B) Control A431 cells and integrin b1 knockdown cells were replated on either
collagen I or fibronectin and monitored by time-lapse microscopy. The proportion of cells with a spread morphology (an adherent area of at least 400mm
2)
was scored at 4-min intervals by analysing the time-lapse videos, one representative experiment of three is shown. Inset panels show phase contrast images
of the cells at the indicated times. (C) Control A431 cells and integrin b1 knockdown cells were assayed for their ability to invade Matrigel. The proportion
of cells invading at least 10mm was scored in three 20  fields and averaged: one representative experiment of three is shown.
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recapitulate the process of tumour cells traversing basement
membranes (Hennigan et al, 1994). Cells were seeded on a filter
that separated them from a thick layer of Matrigel containing
growth factors, after 3 days the number of cells that had crossed
the filter and invaded 10mm or more into the Matrigel were scored.
In total, 16% of control vector expressing cells invaded the
Matrigel while approximately 6% of integrin b1 knockdown cells
were invasive (Figure 3C). To confirm that integrin b1 is required
for A431 cells to efficiently invade Matrigel we used the antibody
AIIB2 to block integrin b1 function. Figure 3D shows that
treatment of A431 cells with AIIB2 inhibited the number of A431
cells invading into Matrigel, while a control antibody had no effect.
These data demonstrate the importance of integrin b1 for VSCC
cells to effectively invade a three-dimensional matrix.
Integrin b1 is not required for cell signalling or
proliferation in adherent cells
Integrin-dependent cell attachment and spreading is accompanied
by the activation of many signal transduction pathways; in
particular focal adhesion kinase (FAK) and ERK/MAP kinase are
activated. Given the defects in adhesion and spreading observed in
the integrin b1 knockdown cells (described above), we tested if
activation of FAK and ERK is compromised in these cells. To
promote integrin-dependent signalling we detached cells and
replated them onto collagen I; cell lysates were made from cells
either immediately prior to replating or 20, 60 or 120min after
replating (we were unable to analyse samples at earlier timepoints
because the integrin b1 knockdown cells were not sufficiently
adherent to collect). Phoshorylation of FAK on tyrosine 397
correlates with its activity (Hanks et al, 2003); we therefore used an
antibody that recognises phosho-Y397 to determine the activity of
FAK. Figure 4A shows that FAK activity was slightly higher in
control cells compared to integrin b1 knockdown cells both prior
to and after replating; similar results were obtained using different
integrin b1 knockdown clones (data not shown). We also
investigated if ERK1/2 activity was altered by monitoring the
phosphorylation of sites that are required for and correlate with
ERK1/2 activity (Her et al, 1993; Marshall, 1994). In contrast to
FAK activity, ERK1&2 activity was increased to similar levels
after replating in integrin b1 knockdown cells. However, before
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Figure 4 Integrin b1 is not required for proliferation or activation of FAK or ERK. (A) Control A431 cells and integrin b1 knockdown cells were detached
and replated onto collagen I. Cell lysates were made at the times indicated (0 is detached cells immediately prior to plating) and analysed for FAK activity by
Western blotting. Upper panel shows phospho-FAK Y397 immunoblot, and lower panel shows total FAK immunoblot – numbers are quantification of
phospho-FAK divided by quantification of total FAK normalised to control cells at time 0. (B) As for ‘(A)’ except lysates were analysed for ERK activity by
Western blotting. Upper panel shows phospho-ERK1/2 T283 and Y285 immunoblot, and lower panel shows total ERK2 immunoblot – numbers are
quantification of phospho-ERK divided by quantification of total ERK normalised to control cells at time 0. (C) 40000 control A431 cells or integrin b1
knockdown cells were seeded in six-well plates. The number of cells in three 20  fields was counted after 24, 48 and 72h. Data shown are the average of
six 20  fields from two experiments with the cell numbers normalised to day 1. The data for the integrin b1 knockdown cells are the average obtained
from the different knockdown cell lines.
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(compare 0 timepoints in Figure 4B). Similar results were obtained
when cells were replated onto fibronectin-coated dishes (data not
shown). These data demonstrate that although integrin b1i s
required for cell spreading it is not required for ERK1/2 activation
and makes only a small contribution to FAK activation after
replating cells on collagen I.
Forced expression of integrin b1 in suprabasal keratinocytes has
been suggested to antagonise cell cycle exit (Carroll et al, 1995; Zhu
et al, 1999), to investigate whether reduced integrin b1 expression
affects proliferation we analysed the ability of the knockdown cell
lines to grow in 5% serum. Control and integrin b1 knockdown
cells were plated at low density and the number of cells counted
after 24, 48 and 72h. To eliminate clone to clone variation we
averaged the growth curves for the three integrin b1 knockdown
cell lines. Integrin b1 knockdown cells grew at the same rate as
control cells (Figure 4C). Apoptosis was not increased in integrin
b1 knockdown cells compared to control cells in either adherent or
nonadherent culture conditions (data not shown).
In vivo analysis of integrin b1 function
The results described above implicate integrin b1 in the motility,
signalling and proliferation of VSCC cells. To investigate the role
of integrin b1 in vivo we injected cells subcutaneously into nude
mice. Eight mice were injected with A431 cells stably transfected
with the empty vector and a total of 15 mice were injected with
three different integrin b1 knockdown clones. To confirm that
integrin b1 remained stably knocked down in vivo we stained
frozen sections of the tumours for integrin b1, keratin 14 to
identify tumour cells and CD31 to identify endothelial cells.
Integrin b1 was clearly expressed in control tumours but not in
integrin b1 knockdown tumours (Figure 5A). No integrin b1
staining was observed from host tissue because the P5D2 antibody
we used does not recognise murine integrin b1. These results
demonstrate that the integrin b1 levels remained knocked-down in
vivo. No difference was observed between the size of control and
integrin b1 knockdown tumours after 11 and 15 days (Figure 5B
and data not shown), indicating that integrin b1 is not required for
the proliferation of VSCC cells in vivo. We next tested if there were
any differences in FAK and ERK/MAP kinase activity in vivo.
Phospho-FAK and phospho-ERK1/2 levels were compared between
tumour lysates by Western blotting. Figure 5C shows that there
was no consistent difference in either FAK or ERK1/2 activity
between control and integrin b1 knockdown tumours.
We have shown that cells lacking integrin b1 have defects in cell
attachment and spreading; in vivo such difference could be
reflected by altered morphological characteristics of the tumours.
We therefore investigated if the histology of the integrin b1
knockdown tumours was different from the control tumours.
When stained with haematoxylin and eosin the internal areas of
the knockdown and control tumours were indistinguishable (data
not shown). However, there was a difference in the appearance of
the tumour margins; the boundaries between the control tumours
and the surrounding dermal tissue were poorly defined with
clusters of carcinoma cells invading the dermis (Figure 5E upper
panels). This pattern of invasion resembles the ‘spray’ pattern of
invasion observed in VSCC (Heaps et al, 1990; Qureshi et al, 1999).
In contrast, the boundaries of integrin b1 knockdown tumours
were better-defined and were often encapsulated by fibroblasts
aligned parallel to the tumour edge (Figure 5E, lower panels). To
further investigate this difference we stained the tumour margins
for keratin 14 to unambiguously identify the tumour cells and
laminin to stain any structures resembling basement membranes.
Control tumours clearly had tumour cells breaking away from the
tumour and there was no organisation of laminin relative to the
tumour boundary. Integrin b1 knockdown tumours had signifi-
cantly fewer cells invading the surrounding dermal tissue.
Furthermore, in some places, tumour cells remained partly
bounded by laminin; however, the laminin was not continuous
or well organised as in an intact basement membrane (compare
Figure 1B and 5E). To quantify this difference, the percentage of
encapsulated tumour boundary was measured in control and
integrin b1 knockdown tumours. Figure 5D shows the relative
proportions of the different morphologies of the tumour
boundaries for the control and integrin b1 knockdown tumours.
In all three integrin b1 knockdown cell lines the proportion of
invasive tumour boundary was reduced and the encapsulated
tumour boundary increased compared to controls (data not
shown). We were unable to determine if integrin b1 is required
for metastasis as we did not observe metastases in any of the mice
(data not shown). These data demonstrate that integrin b1i s
required for invasive tumour margins in vivo.
DISCUSSION
In this paper we have documented the change in integrin
expression in VSCC, with particular focus on the expression and
conformation of integrin b1. In normal epidermis, integrin b1i s
localised to lateral and basal membranes in the basal layer of cells.
The lateral localisation of integrin b1 is somewhat unusual but has
been previously reported by Surico et al (1995). In VSCC the
proportion of cells expressing integrins a2, a3, a5, a6 and b1
increases and their localisation becomes disorganised. In addition,
the levels of integrins a3 and b1 expressed also increase. To
analyse the functional significance of these changes we generated
VSCC cell lines with knocked-down levels of integrin b1. We found
that reducing the levels of integrin b1 in VSCC cells also caused a
reduction in the levels of integrin a3 and a5. Both integrin a3 and
a5 heterodimerise with integrin b1; it is possible than these
integrins are not stable if they are unable to bind to the
appropriate b-subunit. Brakebusch et al (1999) found that
reexpression of integrin b1 in fibroblasts in which the gene had
been deleted led to increased integrin a3 and a5 levels. It is likely
that the increased integrin b1 expression may be needed to allow
the increased levels of integrins a3 and a5 observed in VSCC.
Integrins a3 and a5 only heterodimerise with integrin b1;
therefore, their reduced expression would not be predicted to
have additional consequences in integrin b1 knockdown cells.
Integrin b1 is required for both efficient cell adhesion and
spreading on collagen I. Intriguingly, integrin b1 was not required
for efficient cell adhesion to fibronectin but is necessary for cell
spreading. It is possible that the very low levels of integrin b1
expression in the knockdown clones are sufficient to allow
adhesion to fibronectin but not cell spreading. Alternatively, other
integrins may be able to mediate adhesion to fibronectin, but
integrin b1 may be required to activate intracellular molecules that
mediate cell spreading. In support of this hypothesis, integrin b1
null fibroblasts only show defects in adhering to fibronectin when
excess RGD peptide is added demonstrating that other integrins
can mediate adhesion to fibronectin in the complete absence of
integrin b1 (Brakebusch et al, 1999). We observed altered
organisation of mature focal adhesions and reduced FAK
activation in integrin b1 knockdown cells. These effects may
result from the failure to activate integrin b1-dependent signals
that modulate the remodelling of adhesion complexes. Indeed,
reduced FAK activity may directly contribute to reduced cell
spreading as FAK has been shown to promote cell spreading
(Owen et al, 1999). No defects in cell adhesion to laminin or
vitronectin were observed in integrin b1 knockdown cells (data not
shown), indicating that adhesion to these substrates is mediated by
other integrins, possibly a6b4 and aVb3. Consistent with this, we
found that expression of integrins b3, b4 and a6 was not affected
by integrin b1 knockdown and integrin aV expression was slightly
increased.
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tumours, suggesting that it may be involved in tumour invasion
into the dermis. We find that loss of integrin b1 leads to better-
defined tumour borders; in particular, the amount of tumour
boundary that exhibits a ‘spray-type’ pattern of invasion is
reduced. The requirement for integrin b1 to form effective cell
adhesions to collagen IV probably explains the reduced ability of
cells lacking integrin b1 to invade into a Matrigel matrix since
collagen IV is a major component of Matrigel. Similarly, it is likely
that the reduction in tumour cell invasion in vivo is caused by the
inability of tumour cells lacking integrin b1 to interact with the
ECM at the tumour margin. Consistent with this hypothesis,
ablation of integrin b1 in the skin prevents hair follicle
keratinocytes from re-modelling the basement membrane and
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Figure 5 Analysis of integrin b1 function in tumours in vivo.( A) Frozen sections of tumours formed by control A431 cells or integrin b1 knockdown cells
were stained for integrin b1 (left panels, P5D2 antibody), keratin 14 (right panels, blue) and CD31 (right panels, red). (B)1 0
6 control A431 cells or integrin
b1 knockdown cells were injected subcutaneously into nude mice. The average tumour volume after 15 days is shown (the data for the three integrin b1
knockdown clones were pooled, no statistically significant differences were observed between the three integrin b1 knockdown clones). (C) Lysates were
made from tumours formed by control A431 cells or integrin b1 knockdown cells and analysed by Western blotting for ERK1/2 and FAK activity. Upper
panel shows phospho-FAK Y397 immunoblot, upper-mid panel shows total FAK immunoblot, lower-mid panel shows phospho-ERK1/2 T283 and Y285
immunoblot, and lower panel shows total ERK2 immunoblot. (D) The proportion of encapsulated or invasive tumour boundary (scored blind) is shown for
control and integrin b1 knockdown tumours. *Indicates a statistically significant difference from control (Po0.05). (E) Frozen sections of tumour margins
from control A431 cells (upper panels) or integrin b1 knockdown clone 19 cells (lower panels) were stained with haematoxylin and eosin (left) or for
laminin and keratin 14 (middle and right). ‘*inv’ indicates invasive margin, ‘*enc’ indicates encapsualted margin, ‘d’ – dermis, ‘e’ – host epidermis, ‘t’ – tumour.
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sinvaginating into the dermis (Raghavan et al, 2000). An additional
possibility is that these cells also fail to interact with host cells at
the tumour edge; teratomas derived from integrin b1 deficient cells
recruit lower numbers of host cells in tumours (Bloch et al, 1997).
These results show that loss of integrin b1 affects the invasive
behaviour of VSCC cells in vivo, while integrin b1 has previously
been implicated in the ability of experimentally transformed
fibroblasts and lymphoma cells and to metastasise, it is not clear in
these studies if this is linked to defects in cell invasion or other
tumour cell properties (Stroeken et al, 1998; Brakebusch et al,
1999). In this study we demonstrate that loss of integrin b1 does
not affect the growth of VSCC in vivo or the activation of FAK and
ERK signalling but does affects the invasive behaviour of VSCC
cells in vivo.
Our data suggest that integrin b1 promotes the invasion of
VSCC and this may in turn lead to a worse prognosis.
Unfortunately, the limited number of samples in this study
prevent making correlations between integrin expression levels
and clinical outcome. Agents that block integrin b1 function may
be able to block VSCC invasion in vivo. Intravenous delivery of
antiintegrin b1 antibodies can inhibit neutrophil migration into
sites of pulmonary inflammation (Ridger et al, 2001) and peptides
mimicking integrin ligands can interfere with integrin function in
vivo (Tucker, 2003). Other tumour types may also be effectively
targeted by strategies that block integrin b1 function; mammary
carcinoma cells revert to a normal phenotype when integrin b1i s
inhibited (Weaver et al, 1997).
Loss of integrin b1 did not affect ERK signalling or proliferation
in adherent cells, suggesting that there is redundancy between cell
adhesion molecules in promoting the activation of mitogenic
pathways; although it is possible that very low levels of integrin
b1 remaining in the knockdown cell lines are sufficient to
mediate signalling in adherent cells. Both ERK and FAK activities
were reduced in nonadherent cells with reduced levels of
integrin b1. These results suggest that integrin b1 promotes
the formation of certain signalling complexes even when it is
not bound to ECM in the conventional way. It is possible that
even in nonadherent cells, integrin b1 can engage the fibronectin
present in serum or that unbound integrin b1 has a role in the
formation of signalling complexes. Interestingly, reduced
levels of integrin b1 in vivo did not affect the overall levels of
ERK and FAK signalling or tumour growth; this suggests that for
VSCC cells in vitro adherent culture more closely resembles the
tumour situation than nonadherent cell culture. However, it is
possible that there are particular microenvironments within the
tumour where integrin b1 is required for mitogenic signalling.
Taken together these results demonstrate that in vivo the main
function of integrin b1 in VSCC is to promote cell motility and
invasion and that it is not required for activation of FAK, ERK or
cell proliferation.
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